Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung‐Jue Bang, Yoon‐Koo Kang, Eric Van Cutsem et al.|The Lancet|2010Cited by 7.3k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandalà et al.|The Lancet|2018Cited by 1.3k
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOSTakayuki Yoshino, Jean‐Yves Douillard, Dirk Arnold et al.|Annals of Oncology|2017Cited by 591
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hiroya Taniguchi et al.|Nature Medicine|2020Cited by 366
Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)Narikazu Boku, Atsushi Ohtsu, Suguru Yamamoto et al.|Journal of Clinical Oncology|2007Cited by 158